Global Alzheimers Drugs Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Alzheimer's Disease and Rising Geriatric Population

 


Alzheimers Drugs Market

The global Alzheimers drugs market  is estimated to be valued at US$ 7 billion in 2022 and is expected to exhibit a CAGR of 9.5% over the forecast period of 2017-2025, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:

Alzheimer's disease is a neurodegenerative disorder that affects mainly the elderly population. It is characterized by progressive cognitive impairment, memory loss, and behavioral changes. The market for Alzheimer's drugs includes pharmaceutical products used for the treatment of these symptoms and to slow down the progression of the disease. Key drugs in the market include cholinesterase inhibitors and NMDA receptor antagonists.

B) Market Dynamics:

The market for Alzheimer's drugs is driven by two main factors. Firstly, the increasing prevalence of Alzheimer's disease globally is contributing to the growth of this market. According to the World Alzheimer Report 2019, there were an estimated 50 million people worldwide living with dementia in 2019, and this number is expected to triple by 2050. Secondly, the rising geriatric population is also a significant driver for this market. With advancements in healthcare, life expectancies have increased, leading to a larger proportion of the population being elderly and at a higher risk of developing Alzheimer's disease.

C) Market Key Trends:

One key trend in the Alzheimers drugs market  is the development of disease-modifying drugs. Currently, most available treatments focus on managing symptoms rather than slowing down or halting the progression of the disease. However, several key players in the Alzheimers Drugs Market are investing in research and development to develop drugs that can modify the course of the disease and provide better outcomes for patients. For example, Biogen is conducting clinical trials for its Alzheimer's drug candidate, Aducanumab, which aims to remove amyloid plaques in the brain, a key characteristic of Alzheimer's disease.

D) SWOT Analysis:

Strength:

1. Growing demand for Alzheimer's drugs

2. Advancements in research and development

Weakness:

1. Lack of curative treatment options

2. High cost of Alzheimer's drugs

Opportunity:

1. Untapped markets in developing countries

2. Increasing healthcare expenditure

Threats:

1. Stringent regulations for drug approvals

2. Patent expirations and generic competition

E) Key Takeaways:

- The global Alzheimers drugs market  is expected to witness high growth, exhibiting a CAGR of 9.5% over the forecast period, due to increasing prevalence of Alzheimer's disease and rising geriatric population.

- North America is expected to be the fastest growing and dominating region in the market, driven by the high prevalence of Alzheimer's disease and presence of key market players.

- Key players operating in the global Alzheimers drugs market  include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S, and Teva Pharmaceuticals Industries Ltd.

In conclusion, the global Alzheimers drugs market  is poised for significant growth due to the increasing prevalence of Alzheimer's disease and the aging population. The development of disease-modifying drugs and advancements in research and development present opportunities for market players to provide more effective treatments for patients. However, challenges such as the lack of curative treatment options and high cost of drugs need to be addressed to ensure accessible and affordable healthcare for individuals suffering from Alzheimer's disease.


Comments

Popular posts from this blog

Rising Demand for Nickel Alloys: An In-depth Market Analysis

Video Conferencing Market: Overview, Size, Share, Forecast during year 2020-2028

Regional Analysis and Market Trends: A Comprehensive Study of the Recycled Plastic Granules Market